Evidence map›Paper›PMID 35694239›Full record

ArticleStem cells international2022

Umbilical Cord Mesenchymal Stem Cells Ameliorate Inflammation-Related Tumorigenesis via Modulating Macrophages.

Yanxia Fu, Jun Li, Mengdi Li, Junfeng Xu, Zheng Rong, Fangli Ren, Yinyin Wang, Jianqiu Sheng, Zhijie Chang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. CD126Orphanet journal of rare diseases · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yanxia FuDepartment of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China.ORCID https://orcid.org/0000-0002-1590-2619
Jun LiTsCell Biotech Inc., Beijing 100084, China.
Mengdi LiState Key Laboratory of Membrane Biology, School of Medicine, Institute of Precision Medicine, Tsinghua University, Beijing 100084, China.
Junfeng XuSenior Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
Zheng RongDepartment of Gynaecology and Obstetrics, Jishuitan Hospital, Beijing 100096, China.
Fangli RenState Key Laboratory of Membrane Biology, School of Medicine, Institute of Precision Medicine, Tsinghua University, Beijing 100084, China.
Yinyin WangState Key Laboratory of Membrane Biology, School of Medicine, Institute of Precision Medicine, Tsinghua University, Beijing 100084, China.
Jianqiu ShengDepartment of Gastroenterology, The Seventh Medical Center of PLA General Hospital, Beijing 100700, China.ORCID https://orcid.org/0000-0002-9455-0198
Zhijie ChangState Key Laboratory of Membrane Biology, School of Medicine, Institute of Precision Medicine, Tsinghua University, Beijing 100084, China.ORCID https://orcid.org/0000-0003-1567-3227
State Key Laboratory of Membrane BiologyChinese PLA General Hospital · CNCapital Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) have been documented to be effective for the therapy of inflammation-related diseases but raised concerns on possible tumorigenic effects. Since most of the tumors are induced or promoted by chronic inflammation, one could expect that MSCs might be beneficial for the cancer therapy because of their potent roles on inhibiting inflammation. This study is aimed at performing a safety evaluation and evaluating the role of human umbilical cord mesenchymal stem cells (HUC-MSCs) on tumorigenesis. We found that HUC-MSCs cultured within 20 generations had no significant changes in proliferation, cell cycle, cellular senescence, apoptosis, and expression of mesenchymal stem cell markers. HUC-MSCs were unable to form any tumor in immunodeficiency or normal mice with or without inflammatory stimulation. Intriguingly, we observed that HUC-MSCs inhibited tumorigenesis in B16-derived or AOM/DSS-induced colon cancer models. We reasoned that the effect of HUC-MSCs on tumorigenesis might be through regulating the inflammatory response. Indeed, HUC-MSCs dramatically ameliorated the disease symptoms and pathological changes of DSS-induced colitis mice. We deciphered the mechanism that HUC-MSCs inhibited tumorigenesis through reducing the proportion of macrophages, which were decreased in the mice suffered from AOM/DSS-induced colon cancer. Correspondingly, the expression levels of TNF-

Identifiers

PMID35694239
PMCPMC9178412
OpenAlexW4281617045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.